LON:DDDD 4D pharma (DDDD) Share Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free DDDD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 16.66▼ 16.6652-Week Range N/AVolume1.21 million shsAverage Volume2.96 million shsMarket Capitalization£30.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get 4D pharma alerts: Email Address Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. About 4D pharma Stock (LON:DDDD)4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Read More Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. DDDD Stock News HeadlinesMarch 1, 2024 | markets.businessinsider.com4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)February 7, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About 4D Molecular TherapeuticsFebruary 7, 2024 | msn.com4D Molecular Therapeutics up 3%, prices $300M equityFebruary 5, 2024 | marketwatch.com4D Molecular Shares Hit 52-Week High After 4D-150 Eye Treatment TrialFebruary 5, 2024 | realmoney.thestreet.comHow to Trade a Surging 4D Molecular TherapeuticsFebruary 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)February 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Valeo Pharma (OtherVPHIF) and AbbVie (ABBV)January 30, 2024 | news.yahoo.comIndian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businessesNovember 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS), 4D Molecular Therapeutics (FDMT) and Inari Medical (NARI)November 11, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Xenon (XENE), Adverum Biotechnologies (ADVM) and 4D Molecular Therapeutics (FDMT)November 2, 2023 | markets.businessinsider.comPositive Clinical Trial Results and Future Prospects Reinforce Buy Rating for 4D Molecular Therapeutics: An Analysis by Geulah LivshitsJuly 11, 2023 | markets.businessinsider.comBMO Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)July 5, 2023 | msn.com4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says AnalystApril 28, 2023 | marketwatch.com4D Molecular Down 25% After Wet AMD Drug UpdateApril 27, 2023 | markets.businessinsider.comWhat's Going On With 4D Molecular Therapeutics Stock TodayMarch 24, 2023 | marketwatch.comMicrobiome Therapeutics Market Current Trends, Segmentation, Key Players and Analysis Till 2035February 14, 2023 | marketwatch.comPharmacy Management System Market Scenario 2023 to 2028: New Developments, Economic Situation and Growth ProjectionJanuary 20, 2023 | finance.yahoo.comHuman Microbiome Market Report (2022 to 2030) – Obiome, 4D Pharma, Vedanta Biosciences, Second Genome, Ferring PharmaceuticalsDecember 30, 2022 | thetimes.co.uk4D Pharma rescue by Armistice to face voteOctober 5, 2022 | finance.yahoo.com4D pharma plc (DDDD.L)September 26, 2022 | nasdaq.comThe past year for 4D Molecular Therapeutics (NASDAQ:FDMT) investors has not been profitableJune 30, 2022 | apnews.com4D pharma plc (“4D pharma”) Receives Notice of Delisting From NasdaqJune 25, 2022 | thetimes.co.ukWoodford stock pick 4D Pharma collapsesJune 24, 2022 | finance.yahoo.comUpdate on Suspension of TradingMay 27, 2022 | proactiveinvestors.com.au4D Pharma outlines phase II plans for promising cancer drug candidateSee More Headlines Receive DDDD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today5/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:DDDD CUSIPN/A CIKN/A Webwww.4dpharmaplc.com Phone+44-113-8950130FaxN/AEmployees106Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (15.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-31,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-89.48% Return on Assets-42.64% Debt Debt-to-Equity Ratio39.50 Current Ratio5.21 Quick Ratio4.72 Sales & Book Value Annual Sales£718,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.44 Book ValueGBX 18 per share Price / BookN/AMiscellaneous Outstanding Shares180,340,000Free FloatN/AMarket Cap£30.05 million OptionableNot Optionable Beta2.63 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Duncan Joseph Peyton (Age 53)CEO & Exec. Director Comp: $254kDr. Alexander James Stevenson Ph.D. (Age 51)Chief Scientific Officer & Exec. Director Comp: $218kMr. John Brendan Doyle (Age 45)Chief Financial Officer Ms. Fay WestonHead of Investor RelationsMr. Adrian MurrayGen. Counsel (Interim)Mr. Glenn DouradoExec. VP of Corp. Devel.Ms. Lucy ChristieVP of HRMr. Christophe CariteSr. VP of CMC & Process Devel.Ms. Imke MulderExec. VP of ResearchMore ExecutivesKey CompetitorsC4X DiscoveryLON:C4XDCollagen Solutions plc (COS.L)LON:COSBiodexa PharmaceuticalsLON:MTPHOxford BioDynamicsLON:OBDOKYO PharmaLON:OKYOView All Competitors DDDD Stock Analysis - Frequently Asked Questions How were 4D pharma's earnings last quarter? 4D pharma plc (LON:DDDD) announced its quarterly earnings data on Wednesday, September, 30th. The company reported ($14.06) earnings per share (EPS) for the quarter. What other stocks do shareholders of 4D pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other 4D pharma investors own include Amigo (AMGO), Adamis Pharmaceuticals (ADMP), American Airlines Group (AAL), Boeing (BA), Cineworld Group (CINE), Cray (CRAY), Omega Diagnostics Group (ODX), Oracle (ORCL), Tullow Oil (TLW). How do I buy shares of 4D pharma? Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DDDD) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.